Multicenter Phase II Study of Transanal TME (taTME)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03144765|
Recruitment Status : Active, not recruiting
First Posted : May 9, 2017
Last Update Posted : March 16, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Radical rectal cancer resection, namely total mesorectal excision (TME), is the cornerstone of the treatment of resectable rectal cancer. In combination with chemotherapy and radiation treatment (CRT), complete TME with negative resection margins is associated with sustained local and systemic control even in locally advanced disease. Over the last 2 decades, laparoscopic and robotic techniques have been increasingly adopted due to reduced surgical trauma and faster patient recovery. Yet, both approaches are associated with equivalent postoperative morbidity and disturbances in sexual, urinary and defecatory function relative to open TME. Furthermore, laparoscopic and robotic TME remain associated with substantial conversion rates and variable rates of TME completeness as a result of the procedural difficulties reaching the low rectum from the abdominal approach. Transanal TME (taTME) with laparoscopic assistance was developed to facilitate completion of TME using a primary transanal endoscopic approach. Transanal TME uses a "bottom-up approach" to overcome the technical difficulties of low pelvic dissection using an abdominal approach. Published results from single-center taTME series and an international registry suggest the short-term procedural and oncologic safety of this approach in resectable rectal cancer. No multicenter phase II study has yet been conducted to validate the procedural safety, functional outcomes or long-term oncologic outcomes of this approach.
Study Design: This is a 5-year phase II multicenter single-arm study to evaluate the safety and efficacy of low anterior resection (LAR) with taTME using laparoscopic or robotic assistance in 100 eligible subjects with resectable rectal cancer.
Hypothesis: taTME is non-inferior to standard LAR with respect to the quality of the TME achieved.
|Condition or disease||Intervention/treatment||Phase|
|Rectal Cancer Surgery||Procedure: Transanal Total Mesorectal Excision (taTME)||Not Applicable|
The management of rectal cancer is multidisciplinary and outcomes are dependent on accurate preoperative staging, performance of a curative resection, and the selective use of neoadjuvant and adjuvant therapy to improve long-term oncologic outcomes. Despite the increasing use of laparoscopic and robotic approaches, radical rectal cancer resection is associated with relatively high rates of conversion to open surgery, variable rates of TME specimen completeness, and morbidity rates that are equivalent to that of open TME with respect to infectious and wound-related complications, as well as defecatory, sexual and urinary dysfunction,.
Transanal TME (taTME) with laparoscopic assistance was developed in an effort to facilitate completion of TME using a primarily transanal endoscopic approach. Based on the preliminary results from several published single-center case series and the first international taTME registry, in carefully selected patients with resectable rectal cancer, taTME with laparoscopic assistance is associated with perioperative outcomes and short-term oncologic outcomes that are equivalent to that of standard TME.
This study is the first phase II multicenter trial of taTME conducted in the United States to evaluate the efficacy and safety of taTME with laparoscopic or robotic assistance relative to standard LAR. A total of 100 subjects with resectable rectal cancer located up to 10 cm from the anal verge will be enrolled across 10 US study sites. It is anticipated that this larger, phase II multicenter study will validate the safety and efficacy of taTME with respect to perioperative outcomes, short and long-term oncologic outcomes and functional results.
Study procedures will consist in 1-team (sequential) or 2-team (combined) LAR with transanal TME using laparoscopic or robotic abdominal assistance. Laparoscopic or robotic abdominal access will be obtained followed by inferior mesenteric vessels transection, mobilization or the proximal colon and splenic flexure takedown if indicated. Transanal TME is performed either at the same time or following the above steps. Intersphincteric resection (ISR) may be included for very low tumors. Following pursestring closure of the rectum below the tumor, transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or transabdominally followed by colorectal or coloanal anastomosis, with or without a diverting loop ileostomy. Operative details will be recorded in case report forms (CRF's).
TME pathology assessment:
Resected specimens will be processed and analyzed by the participating institution's Pathology Department according to standard TME protocol. De-identified photographs of all fresh TME specimens will be independently reviewed by a Pathology Review Committee blinded to the source of the specimen.
Postoperative care and follow-up:
Subjects will be managed according to standard postoperative protocols. Postoperative visits and oncology follow-up visits will occur as per standard practice and oncologic outcomes. All adverse events occurring during the study period will be graded using the Clavien-Dindo system. Postoperative functional questionnaires will be obtained 6-8 months and 12-14 months postoperatively in non-diverted subjects. In diverted subjects, functional questionnaires will be collected 3-4 months and 9-10 months following ileostomy closure (or 12-18 months following the study procedure).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) With Laparoscopic Assistance for Rectal Cancer|
|Actual Study Start Date :||August 7, 2017|
|Actual Primary Completion Date :||May 2, 2022|
|Estimated Study Completion Date :||April 2027|
Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
Procedure: Transanal Total Mesorectal Excision (taTME)
Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
Other Name: taTME
- Quality of Mesorectal Excision [ Time Frame: 30 days ]Rate of complete and near-complete mesorectal excision achieved with taTME, based on standard pathologic assessment of TME specimens.
- Complete pathology assessment of TME specimens [ Time Frame: 30 days ]TNM grading, margins assessment
- 30-day perioperative complications [ Time Frame: 30 days ]The rate of complications experienced intraoperatively and postoperatively (within 30 days of the study procedure)
- Long-term postoperative complications [ Time Frame: 12 months ]Incidence of long-term term postoperative complications
- Change in COREFO scores [ Time Frame: 18 months ]Alterations in Colorectal Functional Outcome Questionnaire (COREFO) scores from baseline up to 18 months postoperatively - 27 items. All questions can be answered by choosing from five response options; No; Never; Yes, less than once a week; Yes, 1-2 days per week; Yes, 3-5 days per week; Yes, 6-7 days per week.
- Change in FIQLscores [ Time Frame: 18 months ]Alterations in Fecal Incontinence Quality of Life Instrument (FIQL) scores from baseline up to 18 months postoperatively - 29 items range from 1 (strongly agree) to 4 (strongly disagree); with a 1 indicating a lower functional status of quality of life. Scale scores are only calculated if at least half of the items have been answered.
- Change in Wexner score [ Time Frame: 18 months ]Alterations in Wexner score from baseline up to 18 months postoperatively. Wexner questionnaire - 5 questions and scored from 0 = never to 4= always, with total score from 0 (no incontinence) to 20 (complete incontinence)
- Change in International Index of Erectile Function [IIEF] score [ Time Frame: 18 months ]Alterations in IIEF scores from baseline up to 18 months postoperatively - 15 item questionnaire, each item range from 0 - 5, with total score to 30. lower score indicates more severe erectile dysfunction (ED)
- Change in Female Sexual Function Index [FSFI] [ Time Frame: 18 months ]Alterations in FSFI from baseline up to 18 months postoperatively - 19-item self-report measure, each item ranges from 0-5, with full range from 2 to 36, with low score indicating sexual function disorder.
- Change in IPSS [ Time Frame: 18 months ]Alterations in International Prostate Symptom Score (IPSS) from baseline up to 18 months postoperatively - IPSS 8 questions total - 7 questions related to symptoms, each item scored 1-5. (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 ("delighted" to "terrible".) Total scale ranges from 8-35. Mild (symptom score less than of equal to 7), Moderate (symptom score range 8-19), Severe (symptom score range 20-35).
- 3-year oncologic outcomes [ Time Frame: 3-5 years ]3-year local recurrence rate, distant recurrence rate, disease-free survival and overall survival
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- New diagnosis of histologically confirmed adenocarcinoma of the rectum
- Age ≥18
- Clinical stage cT1 (high-risk), T2, or T3, cN0, N1, N2 on staging pelvic MRI
- Negative predicted CRM on staging pelvic MRI
- No evidence of metastasis on CT scans of the chest, abdomen and pelvis
- Rectal cancer located within 10 cm from the anal verge based on proctoscopy and digital rectal examination (DRE)
- Complete preoperative colonoscopy demonstrating no synchronous colon cancer
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)
- Eligible to undergo laparoscopic or robotic LAR with or without a temporary diverting stoma, based on multidisciplinary tumor board consensus
- Able to understand and willing to sign a written informed consent form
- cT4 on staging pelvic MRI
- >12 weeks delay between completion of neoadjuvant CRT and planned study procedure
- Severely symptomatic rectal tumors
- Tumors invading into the internal anal sphincter muscle based on DRE and pelvic MRI
- Fecal incontinence at baseline
- Prior history of rectal resection
- Prior history of colorectal cancer
- History of inflammatory bowel disease
- Uncontrolled concurrent illness
- Subjects who cannot read or understand English
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03144765
|United States, California|
|Los Angeles, California, United States, 90027|
|Cedars Sinai Medical Center|
|Los Angeles, California, United States, 90048|
|UC Irvine Hospital|
|Orange, California, United States, 92868|
|United States, Florida|
|Orlando, Florida, United States, 32804|
|Cleveland Clinic Florida|
|Weston, Florida, United States, 33331|
|United States, Massachusetts|
|University of Massachusetts|
|Worcester, Massachusetts, United States, 01605|
|United States, New York|
|Mount Sinai Beth Israel|
|New York, New York, United States, 10003|
|Icahn School of Medicine at Mount Sinai|
|New York, New York, United States, 10029|
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|United States, Oregon|
|Providence Portland Medical Center|
|Portland, Oregon, United States, 97213|
|United States, Pennsylvania|
|Wynnewood, Pennsylvania, United States, 19096|
|Toronto Western Hospital|
|Principal Investigator:||Patricia Sylla, MD||Icahn School of Medicine at Mount Sinai|
|Responsible Party:||Patricia Sylla, Associate Professor, Icahn School of Medicine at Mount Sinai|
|Other Study ID Numbers:||
|First Posted:||May 9, 2017 Key Record Dates|
|Last Update Posted:||March 16, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Total mesorectal excision
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases